Vivoryon Therapeutics
Update in progress05Y.F (Frankfurt)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines. Its pipeline targets toxic pGlu-Abeta (N3pE-Abeta) to block its production. The lead candidate PQ912 is a nanomolar QPCT inhibitor that completed Phase IIb for Alzheimer's disease. It also develops the monoclonal antibody PBD-C06 for N3pE-Abeta, with collaborations including Nordic Bioscience, Fraunhofer, and Simcere. Founded in 1997, based in Halle, Germany.
Company score
- Sentiment
- -0.27
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.09
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketFrankfurt (FRA)
- LocationGermany
- CEODr. Frank T. Weber M.D.
- Founded1997
- Employees13
- Websitewww.vivoryon.com
Identifiers
- ISINNL00150002Q7